Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model

<table>Progression of CSF Abeta42/40 ratios in ageing APP-Ld mice; from the age of 15 months onwards, the ratio of Abeta42/40 in CSF decreases.</table>

International Journal of Alzheimer’s Disease

fig3

Figure 3

Figure 3: Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model 

Figure 3 | Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model 